难治性重度抑郁症患者突触增强和氯胺酮快速抗抑郁反应：一项复制研究。
Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: A replication study.
机构信息
Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA.
Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA.
出版信息
Psychiatry Res Neuroimaging. 2019 Jan 30;283:64-66. doi: 10.1016/j.pscychresns.2018.09.001. Epub 2018 Sep 12.
Abstract
Preclinical and clinical evidence has demonstrated that ketamine has rapid antidepressant effects. Studies using pre-treatment with an AMPA inhibitor suggest that enhancing AMPA throughput is crucial to ketamine's effects, including increases in both basal and evoked gamma power. This study sought to replicate previous findings of increased gamma response to a somatosensory stimulus at 230 min and Day 1 in ketamine responders versus non-responders in 31 depressed subjects and 25 healthy controls. A significant difference in peak gamma power was seen in the depressed ketamine responders versus non-responders. These results implicate AMPA throughput in ketamine's mechanism of antidepressant action.
摘要
临床前和临床证据表明氯胺酮具有快速抗抑郁作用。使用 AMPA 抑制剂预处理的研究表明，增强 AMPA 通透性对于氯胺酮的作用至关重要，包括增加基础和诱发γ波的功率。本研究旨在复制先前的研究结果，即在 31 名抑郁患者和 25 名健康对照者中，氯胺酮反应者与非反应者在 230 分钟和第 1 天对躯体感觉刺激的γ反应增加。在抑郁的氯胺酮反应者与非反应者之间观察到峰值γ功率的显著差异。这些结果表明 AMPA 通透性参与了氯胺酮的抗抑郁作用机制。
相似文献
1
Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: A replication study.难治性重度抑郁症患者突触增强和氯胺酮快速抗抑郁反应：一项复制研究。
Psychiatry Res Neuroimaging. 2019 Jan 30;283:64-66. doi: 10.1016/j.pscychresns.2018.09.001. Epub 2018 Sep 12.
2
Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression.突触增强对于治疗抵抗性重度抑郁症患者对氯胺酮的快速抗抑郁反应至关重要。
Biol Psychiatry. 2012 Oct 1;72(7):555-61. doi: 10.1016/j.biopsych.2012.03.029. Epub 2012 Apr 21.
3
Electrophysiological biomarkers of antidepressant response to ketamine in treatment-resistant depression: Gamma power and long-term potentiation.抗抑郁药反应的电生理生物标志物对治疗抵抗性抑郁症的影响：伽马功率和长时程增强。
Pharmacol Biochem Behav. 2020 Feb;189:172856. doi: 10.1016/j.pbb.2020.172856. Epub 2020 Jan 17.
4
Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects.氯胺酮对抑郁和健康受试者具有明显的电生理和行为效应。
Mol Psychiatry. 2019 Jul;24(7):1040-1052. doi: 10.1038/s41380-018-0028-2. Epub 2018 Feb 27.
5
Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.氯胺酮对有酒精使用障碍家族史的受试者的抗抑郁疗效可延长至少四周。
Int J Neuropsychopharmacol. 2014 Oct 31;18(1):pyu039. doi: 10.1093/ijnp/pyu039.
6
Ketamine administration in depressive disorders: a systematic review and meta-analysis.氯胺酮在抑郁症治疗中的应用：一项系统综述和荟萃分析。
Psychopharmacology (Berl). 2014 Sep;231(18):3663-76. doi: 10.1007/s00213-014-3664-5. Epub 2014 Jul 20.
7
Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression.细胞因子水平的变化与难治性抑郁症患者对氯胺酮的快速抗抑郁反应无关。
J Psychiatr Res. 2017 Jan;84:113-118. doi: 10.1016/j.jpsychires.2016.09.025. Epub 2016 Sep 30.
8
Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects.抑郁症患者和健康对照者氯胺酮和安慰剂交叉试验的血浆代谢组学分析。
Psychopharmacology (Berl). 2018 Oct;235(10):3017-3030. doi: 10.1007/s00213-018-4992-7. Epub 2018 Aug 16.
9
Ketamine: The final frontier or another depressing end?氯胺酮：是最终的前沿领域还是又一个令人沮丧的结局？
Behav Brain Res. 2020 Apr 6;383:112508. doi: 10.1016/j.bbr.2020.112508. Epub 2020 Feb 1.
10
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.氯胺酮在情感障碍中的应用综述：临床疗效的现有证据、使用限制以及作用机制的临床前证据。
J Affect Disord. 2014 Mar;156:24-35. doi: 10.1016/j.jad.2013.11.014. Epub 2013 Dec 10.
引用本文的文献
1
Transient peripheral blood transcriptomic response to ketamine treatment in children with ADNP syndrome.ADNP 综合征患儿氯胺酮治疗后的短暂外周血转录组反应。
Transl Psychiatry. 2024 Jul 25;14(1):307. doi: 10.1038/s41398-024-03005-8.
2
Immediate and long-term electrophysiological biomarkers of antidepressant-like behavioral effects after subanesthetic ketamine and medial prefrontal cortex deep brain stimulation treatment.亚麻醉剂量氯胺酮和内侧前额叶皮质深部脑刺激治疗后抗抑郁样行为效应的即时和长期电生理生物标志物
Front Neurosci. 2024 Jun 20;18:1389096. doi: 10.3389/fnins.2024.1389096. eCollection 2024.
3
Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments.氯胺酮与抑郁症的神经生物学：迈向新一代快速抗抑郁治疗方法。
Proc Natl Acad Sci U S A. 2023 Dec 5;120(49):e2305772120. doi: 10.1073/pnas.2305772120. Epub 2023 Nov 27.
4
Mechanisms of Sustained Increases in Power Post-Ketamine in a Computational Model of the Hippocampal CA3: Implications for Ketamine's Antidepressant Mechanism of Action.海马体CA3计算模型中氯胺酮给药后功率持续增加的机制：对氯胺酮抗抑郁作用机制的启示
Brain Sci. 2023 Nov 7;13(11):1562. doi: 10.3390/brainsci13111562.
5
Brain-based correlates of antidepressant response to ketamine: a comprehensive systematic review of neuroimaging studies.基于大脑的抗抑郁药氯胺酮反应的相关性：神经影像学研究的综合系统评价。
Lancet Psychiatry. 2023 Oct;10(10):790-800. doi: 10.1016/S2215-0366(23)00183-9. Epub 2023 Aug 22.
6
Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms.氯胺酮与快速抗抑郁作用：新的治疗方法和新的突触信号转导机制。
Neuropsychopharmacology. 2024 Jan;49(1):41-50. doi: 10.1038/s41386-023-01629-w. Epub 2023 Jul 24.
7
Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial.神经复杂性 EEG 生物标志物在老年难治性抑郁症快速和快速后氯胺酮效应中的研究：一项随机对照试验。
Neuropsychopharmacology. 2023 Oct;48(11):1586-1593. doi: 10.1038/s41386-023-01586-4. Epub 2023 Apr 19.
8
Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment.氯胺酮和血清素能致幻剂：快速抗抑郁治疗作用机制和生物标志物的最新研究进展。
Neuropharmacology. 2023 Mar 15;226:109422. doi: 10.1016/j.neuropharm.2023.109422. Epub 2023 Jan 13.
9
Magnetoencephalography biomarkers of suicide attempt history and antidepressant response to ketamine in treatment-resistant major depression.磁源经颅图生物标志物与自杀史及难治性重度抑郁症患者接受氯胺酮治疗后的抗抑郁反应。
J Affect Disord. 2022 Sep 1;312:188-197. doi: 10.1016/j.jad.2022.06.025. Epub 2022 Jun 18.
10
Transcriptional Activation, Deactivation and Rebound Patterns in Cortex, Hippocampus and Amygdala in Response to Ketamine Infusion in Rats.大鼠静脉注射氯胺酮后皮质、海马和杏仁核的转录激活、失活及反弹模式
Front Mol Neurosci. 2022 May 30;15:892345. doi: 10.3389/fnmol.2022.892345. eCollection 2022.
本文引用的文献
1
Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects.氯胺酮对抑郁和健康受试者具有明显的电生理和行为效应。
Mol Psychiatry. 2019 Jul;24(7):1040-1052. doi: 10.1038/s41380-018-0028-2. Epub 2018 Feb 27.
2
The effects of AMPA blockade on the spectral profile of human early visual cortex recordings studied with non-invasive MEG.使用非侵入性脑磁图研究AMPA阻断对人类早期视觉皮层记录频谱特征的影响。
Cortex. 2016 Aug;81:266-75. doi: 10.1016/j.cortex.2016.03.004. Epub 2016 Mar 31.
3
NMDAR inhibition-independent antidepressant actions of ketamine metabolites.氯胺酮代谢物的非NMDAR抑制依赖性抗抑郁作用。
Nature. 2016 May 26;533(7604):481-6. doi: 10.1038/nature17998. Epub 2016 May 4.
4
Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression.突触增强对于治疗抵抗性重度抑郁症患者对氯胺酮的快速抗抑郁反应至关重要。
Biol Psychiatry. 2012 Oct 1;72(7):555-61. doi: 10.1016/j.biopsych.2012.03.029. Epub 2012 Apr 21.
5
Synaptic AMPA receptor plasticity and behavior.突触AMPA受体可塑性与行为
Neuron. 2009 Feb 12;61(3):340-50. doi: 10.1016/j.neuron.2009.01.015.
6
A new depression scale designed to be sensitive to change.一种旨在对变化敏感的新型抑郁量表。
Br J Psychiatry. 1979 Apr;134:382-9. doi: 10.1192/bjp.134.4.382.
Zotero 插件